ReviewInternational ophthalmology2026
Revisiting the ocular use of chlorhexidine: an agent to remember in multidrug-resistant bacterial and fungal keratitis.
Review in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChlorhexidine, a well-established antiseptic in systemic medicine and dentistry, has long been overlooked in ophthalmology outside its role in Acanthamoeba keratitis. However, recent evidence supports its potential as an effective adjunct or alternative agent in multidrug-resistant (MDR) bacterial keratitis, where treatment options remain limited and therapeutic challenges are escalating. This review aims to revisit ocular use of chlorhexidine.
methodsA comprehensive search was performed in the PubMed database using combinations of the following keywords: "chlorhexidine", "keratitis", "Acanthamoeba keratitis", "fungal keratitis", "bacterial keratitis", "ocularinfections", and "antimicrobial resistance". Studies relevant to the ophthalmological use of chlorhexidine, particularlyin the context of keratitis and antimicrobial resistance, were utilized.
resultsThe results revealed chlorhexidine's antimicrobial mechanisms, ocular formulations, and clinical applications, while highlighting emerging evidence from case reports, retrospective analyses, and in vitro studies that suggest potential activity against MDR ocular pathogens, including extended spectrum beta lactamase (ESBL) producing Enterobacteriaceae, methicillin-resistant Staphylococcus aureus (MRSA), and carbapenem-resistant Pseudomonas spp.
conclusionsAs the threat of antimicrobial resistance rises globally, chlorhexidine merits renewed attention and clinical evaluation within ophthalmology, particularly as a viable and accessible therapeutic option in resistant infections. Although current evidence is limited to preclinical studies and case reports, chlorhexidine shows potential efficacy in MDR and may warrant further investigation in well-designed clinical trials.
Indexed as
Identifiers
42142178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.